Drilldown: Medicines

None (1) · Insulin aspart (1) · Insulin lispro (1)

Humalog, Admelog, Lyumjev (1) · Leqembi (1) · NovoLog, Fiasp (ultra-rapid), Trurapi (1)

Anti-amyloid beta (Aβ) monoclonal antibody (1) · targets protofibrils (1) · [[:Category:Insulins|Insulin]] (2) · [[:Category:Mealtime_insulins|Mealtime (bolus) insulin]] (2) · [[:Category:Rapid-acting_insulins|Rapid-acting insulin analog]] (2)

None (2) · '"`UNIQ--vote-00000584-QINU`"' Binds the same insulin receptor as endogenous insulin with comparable mitogenic-to-metabolic ratio. Ultra-rapid formulations (Lyumjev) add treprostinil and citrate to accelerate absorption further'"`UNIQ--ref-00000585-QINU`"'. (1)

Alzheimer disease (MCI or mild dementia stage); FDA accelerated approval Jan 2023 → traditional approval July 2023 (1) · '"`UNIQ--vote-00000586-QINU`"', '"`UNIQ--vote-00000587-QINU`"', '"`UNIQ--vote-00000588-QINU`"' (1) · '"`UNIQ--vote-000005EF-QINU`"', '"`UNIQ--vote-000005F0-QINU`"', '"`UNIQ--vote-000005F1-QINU`"' (1)

10 mg/kg IV every 2 weeks (1) · SC 4-6 units (or 1 unit per 10-15 g carbs) at meals; titrate to postprandial glucose (1) · SC 4-6 units (or 1 unit per 10-15 g carbs) at meals; titrate to postprandial glucose. Typical total daily dose 0.5-1 U/kg/d split between basal and prandial coverage in T1DM (1)

100 U/mL (Humalog, Admelog, Lyumjev) vials, pens, cartridges; 200 U/mL Humalog KwikPen (1) · 100 U/mL (NovoLog, Fiasp) vials, pens, cartridges (1) · 200 mg/2 mL, 500 mg/5 mL vials for IV infusion (1)

10 mg/kg q2w (1) · Titrated to glucose; no fixed maximum (2)

insulin pumps (2) · IV (1) · IV (continuous infusion for DKA) (1) · IV infusion (60 min) every 2 weeks; outpatient or infusion-center setting (1) · Subcutaneous (2)

SC: 5-15 minutes (Fiasp 2.5 minutes earlier on average) (1) · SC: 5-15 minutes; ultra-rapid Lyumjev faster (1) · Slowing of cognitive decline over 18 months (modest effect, ~27% relative slowing) (1)

None · 24 hours · 4-6 hours · 12 hours · 6-8 hours · Daily dosing · 8-12 hours · 12-24 hours · Hours · Hours per application · 24 hours (HS dosing) · 24 hours (once-daily dosing) · 24 h · N/A · N/A (replacement) · Variable · ~7-8 hours · 3-5 hours · 4-6 hours (IR); 24 hours (ER) · 6-12 hours

Other values:

Search

~1 hour SC'"`UNIQ--ref-00000589-QINU`"' (1) · ~5-7 days (1) · ~80 minutes SC'"`UNIQ--ref-000005F2-QINU`"' (1)

100% (IV) (1) · ~100% from subcutaneous depot (2)

Insulin is the preferred glucose-lowering therapy in pregnancy; aspart is widely used.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Insulin is the preferred glucose-lowering therapy in pregnancy; lispro is widely used.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Limited data (1)

Rx; REMS-like program for ARIA monitoring (1) · [[USLegal:Prescription only|Rx-only]] in US (1) · [[USLegal:Prescription only|Rx-only]] in US (some OTC formulations exist) (1)